Cybin says this is part of an attempt to buildout its development and clinical operations in the United States and Europe.
Going forward, Alexander Belser will serve as Chief Clinical Officer (CCO) and Aaron Bartlone will be Chief Operating Officer (COO). Former COO and Co-Founder Paul Glavine will become the Chief Growth Officer (CGO) and co-founder and former SVP of Business Development John Kanakis will assume the role of Chief Business Officer (CBO).
“We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental healthcare through therapeutic development programs and innovative drug delivery systems. These appointments will serve to strengthen our development and clinical operations globally and solidify Cybin’s position within the industry. Alex and Aaron bring deep clinical, commercial and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets,” stated Doug Drysdale, Chief Executive Officer of Cybin.
Alex Belser began working with Cybin in November as their Chief Clinical Advisor, and, since last June, has been the CCO for Adelia Therapeutics (a company Cybin acquired in December). Belser has a Ph.D. in Counselling Psychology from New York University and was a clinical research fellow at Yale University, where he continues to study the efficacy of psilocybin as a therapeutic treatment.
Aaron Bartlone, Cybin’s new COO, has been a Senior VP of Quality Assurance & Regulatory Affairs with Cybin since last November. Bartlone has experience running companies, having managed the day-to-day operations of AB Dynamix and been the Commercial President at UCB pharma.
As Co-Founders, Paul Glavine and John Kanakis have been at Cybin since the beginning and remain heavily involved.
“Paul and John’s extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the company’s subsequent emergence as a leader within the psychedelics space. Their deep commitment to Cybin’s mission will continue as they assume these new roles and will allow them to further accelerate business development and investor awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level,” added Drysdale.
These moves are all in anticipation of Cybin’s efforts to push into more and more markets and expand clinical testing. They recently completed their 20th pre-clinical studies and began to advance two psychedelic molecules to studies that will allow them to be tested as Investigational New Drugs (INDs).
Cybin’s efforts at expansion are part of a larger pattern of growth in their sector, as the psychedelic drug market is expected to reach $6.85 billion USD by 2027.
Following the news, CYBN.NE’s stock price fell 3 cents to $1.29.
Full disclosure: Cybin is an Equity.Guru marketing client.